Cite

HARVARD Citation

    Caiazza, F. et al. (2016). Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells. Endocrine-related cancer. 23 (4), pp. 323-334. [Online]. 
  
Back to record